0 10 Peripheral peripheral JJ 11 12 T t NN 13 24 lymphocytes lymphocyte NNS 25 29 from from IN 30 35 women woman NNS 36 40 with with IN 41 47 breast breast NN 48 54 cancer cancer NN 55 62 exhibit exhibit VBP 63 71 abnormal abnormal JJ 72 79 protein protein NN 80 90 expression expression NN 91 93 of of IN 94 101 several several JJ 102 111 signaling signal VBG 112 121 molecules molecule NNS 121 122 . . . 124 126 We we PRP 127 135 examined examine VBD 136 145 signaling signal VBG 146 155 molecules molecule NNS 156 158 of of IN 159 169 peripheral peripheral JJ 170 175 blood blood NN 176 177 T t NN 178 189 lymphocytes lymphocyte NNS 190 198 obtained obtain VBN 199 203 from from IN 204 209 women woman NNS 210 214 with with IN 215 221 breast breast NN 222 228 cancer cancer NN 228 229 . . . 230 232 In in IN 233 234 6 6 CD 235 237 of of IN 238 240 14 14 CD 241 249 patients patient NNS 249 250 , , , 251 252 T t NN 253 264 lymphocytes lymphocyte NNS 265 274 displayed display VBD 275 277 an an DT 278 286 impaired impaired JJ 287 294 ability ability NN 295 297 to to TO 298 309 translocate translocate VB 310 314 NFeB NFeB NNP 315 318 p65 p65 NN 319 320 ( ( ( 320 325 Rel-A Rel-A NNP 325 326 ) ) ) 327 336 following follow VBG 337 347 activation activation NN 348 350 by by IN 351 359 anti-CD3 anti-cd3 NN 360 363 and and CC 364 368 IL-2 il-2 NN 368 369 . . . 370 374 This this DT 375 386 observation observation NN 387 390 was be VBD 391 395 made make VBN 396 403 despite despite IN 404 410 normal normal JJ 411 422 cytoplasmic cytoplasmic JJ 423 429 levels level NNS 430 432 of of IN 433 436 the the DT 437 442 Rel-A Rel-A NNP 443 450 protein protein NN 450 451 . . . 452 454 We we PRP 455 459 also also RB 460 468 detected detect VBD 469 479 abnormally abnormally RB 480 483 low low JJ 484 490 levels level NNS 491 493 of of IN 494 497 the the DT 498 507 signaling signal VBG 508 517 molecules molecule NNS 518 524 T-cell t-cell NN 525 533 receptor receptor NN 534 535 ( ( ( 535 544 TCR)-zeta TCR)-zeta NNP 544 545 , , , 546 552 ZAP-70 zap-70 NN 553 556 and and CC 557 563 p56lck p56lck NN 564 566 in in IN 567 568 4 4 CD 569 571 of of IN 572 574 14 14 CD 575 581 breast breast NN 582 588 cancer cancer NN 589 597 patients patient NNS 597 598 , , , 599 603 i.e. i.e. FW 603 604 , , , 605 612 defects defect NNS 613 615 in in IN 616 622 T-cell t-cell NN 623 632 signaling signal VBG 633 642 molecules molecule NNS 642 643 . . . 644 645 T t NN 646 657 lymphocytes lymphocyte NNS 658 662 from from IN 663 664 6 6 CD 665 667 of of IN 668 671 the the DT 672 674 14 14 CD 675 683 patients patient NNS 684 688 also also RB 689 698 exhibited exhibit VBD 699 701 an an DT 702 711 increased increase VBN 712 722 expression expression NN 723 725 of of IN 726 729 the the DT 730 734 dual dual JJ 735 746 specificity specificity NN 747 758 phosphatase phosphatase NN 758 759 , , , 760 763 map map NN 764 770 kinase kinase NNP 771 784 phosphatase-1 phosphatase-1 NN 785 786 ( ( ( 786 791 MKP-1 mkp-1 NN 791 792 ) ) ) 792 793 . . . 794 799 MKP-1 mkp-1 NN 800 811 inactivates inactivate VBZ 812 815 MAP MAP NNP 816 822 kinase kinase NNP 823 826 and and CC 827 836 therefore therefore RB 837 840 may may MD 841 850 interfere interfere VB 851 855 with with IN 856 859 the the DT 860 870 activation activation NN 871 873 of of IN 874 879 c-jun c-jun NN 880 883 and and CC 884 889 c-fos c-fos NN 889 890 . . . 891 904 Abnormalities abnormality NNS 905 907 of of IN 908 909 I I PRP 910 912 or or CC 913 917 more more JJR 918 927 signaling signal VBG 928 937 molecules molecule NNS 938 942 were be VBD 943 948 found find VBN 949 951 in in IN 952 953 9 9 CD 954 956 of of IN 957 959 14 14 CD 960 968 patients patient NNS 968 969 ; ; : 970 977 however however RB 977 978 , , , 979 983 only only RB 984 985 3 3 CD 986 994 patients patient NNS 995 998 had have VBD 999 1000 T t NN 1001 1006 cells cell NNS 1007 1011 that that WDT 1012 1021 exhibited exhibit VBD 1022 1025 all all DT 1026 1027 5 5 CD 1028 1035 defects defect NNS 1035 1036 . . . 1037 1040 Our our PRP$ 1041 1045 data datum NNS 1046 1050 have have VBP 1051 1063 implications implication NNS 1064 1067 for for IN 1068 1071 the the DT 1072 1081 detection detection NN 1082 1084 of of IN 1085 1096 potentially potentially RB 1097 1110 dysfunctional dysfunctional JJ 1111 1112 T t NN 1113 1118 cells cell NNS 1119 1121 in in IN 1122 1130 patients patient NNS 1131 1135 with with IN 1136 1142 cancer cancer NN 1142 1143 . . . 1144 1147 For for IN 1148 1155 example example NN 1155 1156 , , , 1157 1160 the the DT 1161 1169 analysis analysis NN 1170 1172 of of IN 1173 1177 only only RB 1178 1179 1 1 CD 1180 1189 signaling signal VBG 1190 1198 molecule molecule NN 1199 1202 may may MD 1203 1208 allow allow VB 1209 1217 patients patient NNS 1218 1222 with with IN 1223 1234 significant significant JJ 1235 1242 defects defect NNS 1243 1245 in in IN 1246 1252 T-cell T-cell NNP 1253 1262 signaling signaling NN 1263 1265 to to TO 1266 1268 go go VB 1269 1278 unnoticed unnoticed JJ 1278 1279 . . . 1280 1287 Finally finally RB 1287 1288 , , , 1289 1296 despite despite IN 1297 1305 impaired impaired JJ 1306 1311 Rel-A Rel-A NNP 1312 1325 translocation translocation NN 1325 1326 , , , 1327 1328 T t NN 1329 1334 cells cell NNS 1335 1339 were be VBD 1340 1347 capable capable JJ 1348 1350 of of IN 1351 1363 transcribing transcribe VBG 1364 1368 IL-2 il-2 NN 1368 1369 . . . 1370 1381 Impairments impairment NNS 1382 1384 in in IN 1385 1388 the the DT 1389 1402 translocation translocation NN 1403 1405 of of IN 1406 1411 Rel-B Rel-B NNP 1412 1415 and and CC 1416 1421 c-Rel c-rel NN 1422 1429 further further RB 1430 1437 suggest suggest VBP 1438 1442 that that IN 1443 1446 the the DT 1447 1451 NFKB NFKB NNP 1452 1458 family family NN 1459 1466 members member NNS 1467 1472 Rel-A Rel-A NNP 1472 1473 , , , 1474 1479 Rel-B Rel-B NNP 1480 1483 and and CC 1484 1489 c-Rel c-rel NN 1490 1493 are be VBP 1494 1497 not not RB 1498 1506 required require VBN 1507 1510 for for IN 1511 1514 the the DT 1515 1528 transcription transcription NN 1529 1531 of of IN 1532 1536 IL-2 il-2 NN 1537 1539 in in IN 1540 1543 the the DT 1544 1554 peripheral peripheral JJ 1555 1556 T t NN 1557 1568 lymphocytes lymphocyte NNS 1569 1571 of of IN 1572 1580 patients patient NNS 1581 1585 with with IN 1586 1592 breast breast NN 1593 1599 cancer cancer NN 1599 1600 . . .